Skip to main content

Riabni

Pronunciation: re-AB-nee
Generic name: rituximab-arrx
Dosage form: injection for intravenous infusion (100 mg/10 mL, 500 mg/50 mL)
Drug class: CD20 monoclonal antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on May 2, 2025.

What is Riabni?

Riabni is a biosimilar of Rituxan approved to treat:

Riabni (rituximab-arrx) gained FDA approval on December 17, 2020, and was the third biosimilar of Rituxan to be approved.

Side effects

The most common side effects of Riabni are:

In adults with GPA or MPA, the most common side effects of Riabni also include:

Other side effects of Riabni are:

Serious side effects and warnings

Riabni carries a Boxed Warning for fatal infusion-related reactions, severe skin reactions, hepatitis B virus reactivation, and a rare brain condition called progressive multifocal leukoencephalopathy (PML).

Riabni can cause the following serious side effects:

TLS can happen within 12 to 24 hours after an infusion of Riabni. Your healthcare provider may do blood tests to check you for TLS. Your healthcare provider may give you medicine to help prevent TLS. Tell your healthcare provider right away if you have any of the following signs or symptoms of TLS:

Your healthcare provider will stop treatment with Riabni if you have severe, serious, or life-threatening side effects.

Get emergency medical help if you have signs of an allergic reaction to Riabni, such as hives, difficulty breathing, swelling in your face or throat, or a severe skin reaction (symptoms may include fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

These are not all of the possible side effects of Riabni. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088

Before taking this medicine

Before you receive Riabni, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

Riabni may harm an unborn baby. Talk to your healthcare provider about the risks to an unborn baby if you or someone you are caring for receives Riabni during pregnancy. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test to check for pregnancy before starting Riabni.

Effective birth control (contraception) should be used during treatment with Riabni and for 12 months after the last dose. Talk to your healthcare provider about effective birth control.

Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Riabni.

Breastfeeding

Riabni may pass into your breast milk. It is not safe to breastfeed a baby while you are using this medicine. Do not breastfeed during treatment and for 6 months after your last dose of Riabni.

How is Riabni given?

Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using Riabni.

Riabni is given as an infusion into a vein. A healthcare provider will give you this injection.

Riabni is not given daily. Your schedule will depend on the condition being treated. Follow your doctor's dosing instructions very carefully.

Before each injection, you may be given other medications to prevent certain side effects of rituximab.

You will need frequent medical tests.

If you've ever had hepatitis B, using Riabni can cause this virus to become active or get worse. You may need frequent liver function tests while using this medicine and for several months after you stop.

If you need surgery, tell the surgeon ahead of time that you are using Riabni.

What happens if I miss a dose?

Call your doctor if you miss an appointment for your Riabni.

What happens if I overdose?

Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

What should I avoid while receiving Riabni?

Do not receive a "live" vaccine while using Riabni. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.

What other drugs will affect Riabni?

Tell your doctor about all your other medicines, especially:

This list is not complete. Other drugs may affect Riabni, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Does Riabni interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Ingredients

Active ingredient: rituximab-arrx

Inactive ingredients: polysorbate 80, sodium chloride, sodium citrate dihydrate, and Water for Injection, USP.
Hydrochloric acid is used to adjust the buffer solution pH.

Manufacturer

Riabni is manufactured by Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA.

Riabni Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Riabni.

Rituxan (rituximab) - Genentech, Inc.
Formulation type Strength
Single-Dose Vial 100 mg/10 mL (10 mg/mL)
Single-Dose Vial 500 mg/50 mL (10 mg/mL)

View Rituxan information in detail.

Rituxan biosimilar products

Biosimilar products can only be dispensed in place of the reference product if the healthcare provider specifically prescribes the biosimilar product by name.

Pharmacy laws for biosimilar prescribing may vary by state

Riabni (rituximab-arrx) - Amgen Inc.
Formulation type Strength
Single-Dose Vial 100 mg/10 mL (10 mg/mL)
Single-Dose Vial 500 mg/50 mL (10 mg/mL)
Ruxience (rituximab-pvvr) - Pfizer Ireland Pharmaceuticals
Formulation type Strength
Single-Dose Vial 100 mg/10 mL (10 mg/mL)
Single-Dose Vial 500 mg/50 mL (10 mg/mL)

View Ruxience information in detail.

Truxima (rituximab-abbs) - CELLTRION, Inc.
Formulation type Strength
Single-Dose Vial 100 mg/10 mL (10 mg/mL)
Single-Dose Vial 500 mg/50 mL (10 mg/mL)

View Truxima information in detail.

Popular FAQ

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016.

Continue reading
What is the difference between Truxima and Rituxan?

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?

Treatment with Rituxan (rituximab) successfully improves patient outcomes in patients with rheumatoid arthritis including reducing symptoms, reducing levels of fatigue and disability, and increasing health-related quality of life. It also slows the progression of structural damage in joints. Continue reading

What causes infusion reactions to rituximab?

Rituximab infusion reactions are caused primarily by cytokine release in the body. Cytokines are immune system proteins in the body that help to fight infections but can cause an inflammatory response. Infusion reactions may cause hives, itching, shortness of breath, chest pain or dizziness and are a very common side effect of treatment with rituximab (Rituxan). Continue reading

What is the difference between Rituxan and Rituxan Hycela?

Rituxan (rituximab) is administered intravenously (IV), while Rituxan Hycela is given subcutaneously (SC). Continue reading

More FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.